Latest news with #TramadolTablets
Business Standard
09-05-2025
- Business
- Business Standard
Senores Pharmaceuticals's arm inks pact to acquire Tramadol tablets
Senores Pharmaceutical announced that its wholly-owned subsidiary, Senores Pharmaceuticals, Inc., USA (SPI), has signed an agreement to acquire the USFDA-approved abbreviated new drug application (ANDA) for Tramadol tablets from APDM Pharmaceuticals. Tramadol is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The acquisition of this product adds to Senores growing portfolio of pain management therapies and is in line with the companys strategic focus on expanding its presence in the U.S. generics market. According to IQVIA, the market size of Tramadol Tablets in the U.S. was approximately $61.95 million for the 12-month period ending December 2024. As per the specialty data aggregator Symphony, the market was valued at approximately $119.09 million for the 12-month period ending March 2025. The acquisition will be funded through the initial public offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the red herring prospectus. Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024. Shares of Senores Pharmaceuticals rose 0.48% to Rs 484 on the BSE.
Business Standard
09-05-2025
- Business
- Business Standard
Senores Pharmaceuticals Inc. to acquire USFDA approved ANDA for Tramadol Tablets
From APDM Pharmaceuticals Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Tramadol Tablets from APDM Pharmaceuticals (APDM). Tramadol is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The market size of Tramadol Tablet in the USA was ~USD 61.95 Mn (MAT December 2024)1 as per IQVIA and ~USD 119.09 Mn (MAT March 2025)2 as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Business Upturn
09-05-2025
- Business
- Business Upturn
Senores Pharmaceuticals acquires USFDA-approved ANDA for Tramadol Tablets from APDM Pharmaceuticals
By Aman Shukla Published on May 9, 2025, 09:04 IST Senores Pharmaceuticals Limited (SPL), through its wholly-owned US subsidiary, Senores Pharmaceuticals, Inc. (SPI), has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Tramadol Tablets from APDM Pharmaceuticals Private Limited (APDM). Tramadol is an opioid analgesic used for managing moderate to severe pain when alternative treatments are inadequate. This acquisition strengthens SPL's position in the US generic pharmaceutical market. According to IQVIA, the US market size for Tramadol Tablets stood at approximately USD 61.95 million for the 12 months ending December 2024. Data from Symphony, a specialty data aggregator, estimates the market at around USD 119.09 million for the 12 months ending March 2025. The acquisition will be funded through proceeds raised by SPL's Initial Public Offering (IPO), aligning with the objectives stated in its Red Herring Prospectus. This strategic move highlights SPL's focus on expanding its US product portfolio and enhancing revenue growth through high-demand generic drugs. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
